{
  "docId": "019de074-7886-752e-a283-7bf57c077b30",
  "docSlug": "0ac137ebdbf597da5ec73bb0ea218c10",
  "documentTitle": "ATAI | Investor Presentation Deck | 31 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 31,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a split-layout with a sidebar for product specs and a main area for study design and results.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-7886-752e-a283-7bf57c077b30/19",
  "deckHref": "/decks/019de074-7886-752e-a283-7bf57c077b30",
  "deckJsonHref": "/decks/019de074-7886-752e-a283-7bf57c077b30.json",
  "deckAnchorHref": "/decks/019de074-7886-752e-a283-7bf57c077b30#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.6,
        "x": 0.36,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "PCN-101 PHASE 2A STUDY IN PATIENTS WITH TREATMENT RESISTANT DEPRESSION (N=102)",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9de7be4f-0a4c-4bde-91cb-b2128a843777",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.36,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "Note: MADRS = Montgomery-Asberg Depression Rate Scale, CADSS = Clinician-administered dissociative states scale, IV = Intravenous, PBO = Placebo. 1. Ownership percentage... 2. Leal et al... 3. NCT05414422",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fbb8ae4e-d166-467a-85f9-d1477ad6a52f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.3,
        "x": 0.03,
        "y": 0.16
      },
      "kind": "list",
      "text": "OWNERSHIP: 58.9% | PRODUCT: Subcutaneous R-ketamine | PHARMACOLOGY: Glutamatergic modulator | FEATURES: Rapid-acting, non-dissociative | INDICATIONS: TRD, SUD | STATUS: Phase 2a data Jan 2023 | IP: Issued methods | HIGHLIGHT: Third party study",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "10dcb502-c0e9-4543-86a9-57d1cea08c02",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.6,
        "x": 0.36,
        "y": 0.6
      },
      "kind": "list",
      "text": "1. Study did not meet primary endpoint | 2. Mean change on MADRS was -15.3 vs -13.7 | 3. Encouraging signals of efficacy | 4. Generally well-tolerated",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "345802b6-cf79-4901-bfe9-0eed10c71c97",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.36,
        "y": 0.07
      },
      "kind": "title",
      "text": "We’ve completed a Phase 2a study for PCN-101 and are evaluating next steps for the program",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b3b90a36-98c4-4133-9132-33a9b4d5812f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.25,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "SUMMARY: PCN-101",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a38e7bf-52a5-4290-8941-a6b956b83a1a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "executive-summary",
      "slug": null,
      "matchId": "225f0488-a7a0-4e0f-a87e-e8dce20ce352",
      "evidence": "Structured summary of product and clinical trial results",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 24,
      "from": 9,
      "beatId": "7fd3e95d-372d-48f7-909d-f8c5c51d3874",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The document highlights various traction points, including clinical study results and data.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}